The first subjects dosed successfully with no adverse events in the phase I trial of BSG005
April 19, 2022: Biosergen AB (“Biosergen” or the “Company”) today announced that there were no adverse events at all reported after the first volunteers have been dosed with the Company’s proprietary antifungal drug candidate BSG005.The Company has received the first safety review group outcome of the safety and laboratory data following this first administration of BSG005 in the phase I study in Australia. The review of the data revealed that there were no adverse events reported at all and all laboratory data were OK. This is very positive news and also promising for the next dose